Commission Implementing Regulation (EU) 2022/1107 of 4 July 2022 laying down common specifications for certain class D in vitro diagnostic medical devices in accordance with Regulation (EU) 2017/746 of the European Parliament and of the Council (Text with EEA relevance)
Annex IXANNEX IX
In force · version of Jul 25, 2022
COMMON SPECIFICATIONS FOR DEVICES INTENDED FOR DETECTION OR QUANTIFICATION OF MARKERS OF CYTOMEGALOVIRUS (CMV) INFECTION
Scope
This Annex applies to devices intended for detection or quantification of markers of cytomegalovirus (CMV) infection.
Table 1 applies to first-line assays for total antibodies against CMV (total anti-CMV) and IgG antibodies against CMV (anti-CMV IgG).
Table 2 applies to qualitative and quantitative NAT devices for CMV DNA.
Table 1. First-line assays: total anti-CMV and anti-CMV IgG
Performance characteristic Specimens Specimen number, features, use Acceptance criteria Diagnostic sensitivity Positive specimens ≥400 including specimens from recent and past CMV infection, low and high positive titre specimens ≥ 99% sensitivity for confirmable past infection ( 1 ) ; overall sensitivity including recent infection ( 2 ) shall be at least equivalent to the comparator device Seroconversion panels To be tested when available Diagnostic sensitivity during seroconversion shall represent the state of the art Analytical sensitivity Standards WHO International Standard anti-CMV IgG (PEI-code 136616/17) In case of titre determinations and quantitative statements Diagnostic specificity Negative specimens ≥400 ( 3 ) CMV negative specimens from unselected donors, as compared to another CMV test. ≥ 99% Hospitalised patients ( 4 ) ≥200 Potential limitations for specificity, if any, shall be identified Cross-reactivity Potentially cross-reacting ( 5 ) specimens ≥100 in total (e.g. RF+, related viruses or other infectious agents, pregnant women, etc.)
Table 2. Qualitative and quantitative NAT devices for CMV DNA
1. For target sequence amplification devices, a functionality control for each specimen (internal control) shall reflect the state of the art. This control shall as far as possible be used throughout the whole process, i.e. extraction, amplification/hybridisation, detection.
2. Genotype and/or subtype detection shall be demonstrated by appropriate primer or probe design validation and shall also be validated by testing characterised genotyped specimens.
3. Potential cross-reactivity of non-target nucleic acid sequences shall be analysed by appropriate primer or probe design validation and shall also be validated by testing selected specimens.
4. Results of quantitative NAT devices shall be traceable to international standards or calibrated reference materials, if available, and be expressed in international units utilised in the specific field of application. Performance characteristic Specimens Specimen numbers, features, use Acceptance criteria Analytical sensitivity WHO First International Standard Human CMV DNA (09/162; 5 000 000 IU/vial) (or calibrated reference materials) NAT sensitivity and NAT LOD shall be validated by dilution series of reference materials, testing of replicates (minimum 24) at different analyte concentrations, including those with transition from positive to negative results with the respective NAT device. LOD shall be expressed as 95% positive cut-off value (IU/ml) after statistical analysis (e.g. Probit). ( 6 ) quantitative NAT: definition of lower, upper quantification limit, precision, accuracy, ‘linear’ measuring range, ‘dynamic range’. Reproducibility at different concentration levels According to the state of the art Diagnostic sensitivity CMV Strain sensitivity Patient specimens determined as CMV DNA positive by comparator device Dilution series of CMV positive cell cultures may serve as potential substitutes Qualitative NAT: ≥100 Quantitative NAT: ≥100 dilution series for demonstration of quantification efficiencies According to the state of the art Diagnostic specificity Blood donor specimens Qualitative NAT: ≥500 Quantitative NAT: ≥100 According to the state of the art Cross-reactivity Potentially cross-reacting specimens ≥20 specimens in total Including human specimens positive for related human herpesviruses, e.g. EBV, HHV6, VZV Herpesvirus positive cell cultures may serve as potential substitutes According to the state of the art Carry-over High CMV DNA positive; CMV DNA negative At least five runs with alternating high-positive and negative specimens shall be performed during robustness studies. The virus titres of the high positive specimens shall be representative of high virus titres occurring naturally. According to the state of the art Whole system failure rate CMV DNA low-positive ≥100 CMV DNA low-positive specimens shall be tested. These specimens shall contain a virus concentration equivalent to three times the 95 % positive cut-off virus concentration. ≥99% positive